Actuate Therapeutics (ACTU) Return on Assets (2024 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Return on Assets of 0.01% for Q4 2025, up 1.0% year-over-year from 0.01% in Q4 2024, and up 28.02% quarter-over-quarter from 0.02% in Q3 2025.
Actuate Therapeutics (ACTU) Return on Assets (2024 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Return on Assets for 2 consecutive years, with 0.01% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Assets rose 1.0% year-over-year to 0.01%; the TTM figure through Dec 2025 stood at 0.01% (up 1.0% YoY), while the FY2025 annual figure was 0.02%, up 8.0% from the prior year.
- Return on Assets improved to 0.01% in Q4 2025 per ACTU's latest filing, from 0.02% in the prior quarter.
- Across five years, Return on Assets topped out at 0.01% in Q4 2025 and bottomed at 0.04% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 0.00% |
| 10 | Actuate Therapeutics | 29.60 Mn | 29.60 Mn | - | -0.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.02% |
| Jun 30, 2025 | -0.04% |
| Mar 31, 2025 | -0.03% |
| Dec 31, 2024 | -0.02% |
| Sep 30, 2024 | -0.03% |